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Abstract 
Despite the clinical efficacy of anthracycline agents such as doxorubicin, dose-limiting cardiac 
toxicities significantly limit their long-term use. Here, we present the case of a 33-year-old 
female patient with extensive metastatic ER+/PR+/HER2– mucinous adenocarcinoma of the 
breast, who was started on doxorubicin/cyclophosphamide therapy after progressing on 
paclitaxel and ovarian suppressor goserelin with aromatase inhibitor exemestane. The patient 
was comanaged by cardiology, who carefully monitored measures of cardiac function, in-
cluding EKGs, serial echocardiograms, and profiling of lipids, troponin, and pro-BNP every 2 
months. The patient was treated with the cardioprotective agent dexrazoxane, and changes 
in cardiac markers [e.g. decreases in ejection fraction (EF)] were immediately addressed by 
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therapeutic intervention with the ACE inhibitor lisinopril and beta-blocker metoprolol. The 
patient had a complete response to doxorubicin therapy, with a cumulative dose of 1,350 
mg/m
2
, which is significantly above the recommended limits, and to our knowledge, the 
highest dose reported in literature. Two and a half years after the last doxorubicin cycle, the 
patient is asymptomatic with no cardiotoxicity and an excellent quality of life. This case high-
lights the importance of careful monitoring and management of doxorubicin-mediated car-
diotoxicity, and that higher cumulative doses of anthracyclines can be considered in patients 
with ongoing clinical benefit. © 2016 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Anthracyclines, such as doxorubicin (adriamycin), are a class of drugs that have been 
used in cancer chemotherapy regimens in a large number of tumor types since their discov-
ery in the 1970s [1]. These agents exert anticancer effects by binding topoisomerase-II 
(topo2) and intercalating with DNA to inhibit macromolecular biosynthesis [2]. In breast 
cancer, anthracyclines are a mainstay of adjuvant breast cancer treatment either alone or in 
combination with other cytotoxic therapy [3]. However, these drugs are commonly associat-
ed with cardiac toxicity which significantly limits their long-term use, even in the case of 
ongoing response [4]. 
Current guidelines are limited in that they fail to address high-risk patient populations, 
where the benefit of higher cumulative doses of anthracyclines has the potential to outweigh 
the risks. In this case report, we describe a patient with extensive metastatic estrogen recep-
tor-positive (ER+) breast cancer, who achieved a complete response on well-managed pro-
longed doxorubicin treatment with a total cumulative dose of 1,350 mg/m2. Here, we 
demonstrate that higher cumulative doses of anthracyclines can be considered in patients 
with ongoing clinical benefit, and that a multidisciplinary approach to early detection and 
treatment of asymptomatic cardiac dysfunction can maximize the risk-benefit ratio for an-
thracycline-based therapy. 
Case Report 
In December 2010, a 33-year-old woman presented with a 2-week history of moderate 
left hip pain and a lump in her stomach. On exam, a mildly tender palpable mass was noted 
in her epigastrium, with pain upon flexion, abduction and rotation of her left hip without 
atrophy or weakness. An abdominal CT was performed showing a large heterogeneous mass 
replacing the majority of the left lobe of the liver. CT of the chest and pelvis showed 4 inde-
terminate pulmonary nodules, all smaller than 5 mm, and an osseous metastasis in the ante-
rior left acetabulum. The patient was 4 months postpartum and still lactating but a possibly 
4-cm mass was noted in the left breast with bilateral lobular irregularities consistent with 
lactation. PET scan confirmed hypermetabolic breast, liver, and acetabular lesions, with ad-
ditional detection of small hypermetabolic masses in the sacrum, inferior pubic ramus, and 
bilateral ovaries. Biopsy of left breast mass and metastatic liver lesion revealed histologically 
similar ER+/PR+/HER2– mucinous adenocarcinoma (Fig. 1). 
In January 2011, the patient was started on chemotherapy with weekly paclitaxel (80 
mg/m2) and monthly zoledronic acid (4 mg), which led to initial stable disease with clinical 
improvement. After 4 cycles (July 2011), restaging CT demonstrated progressive disease, 
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leading to the substitution of paclitaxel with ovarian suppression by goserelin and the aro-
matase inhibitor exemestane plus the bone-targeted agent denosumab. After 3 months on 
hormone therapy, the patient progressed further. In November 2011, the decision was made 
to pursue doublet therapy consisting of 60 mg/m2 doxorubicin and 600 mg/m2 cyclophos-
phamide with continuation of denosumab (120 mg monthly). At baseline, PET scan revealed 
extensive hypermetabolic regions in the liver and right acetabulum (Fig. 2a). After 8 cycles 
(May 2012), with a cumulative doxorubicin dose of 444 mg/m2 (20% dose reduction for 
cycles 6–8), PET scan revealed no residual disease in the left breast, 75% reduction of activi-
ty in the liver, minimal residual activity in the acetabulum, and no new areas of disease (Fig. 
2b). In a PET scan taken on cycle 22 (June 2013; cumulative doxorubicin dose of 1,116 
mg/m2), the patient achieved nearly complete resolution of disease by PET (Fig. 2c). Com-
plete response was achieved on cycle 24 (August 2013; cumulative dose of 1,200 mg/m2) 
and maintained through cycle 30 (May 2014; a cumulative dose of 1,350 mg/m2) (Fig. 2d), 
after which a multidisciplinary tumor board recommended the patient be switched to sec-
ond-line anti-estrogen fulvestrant with continuation of denosumab monthly. 
As cardiotoxicity is the primary concern for doxorubicin-based therapy, the patient was 
closely comanaged by cardiology over the course of treatment. Cardioprotective iron chela-
tor dexrazoxane was initiated with cycle 6 (March 2012; cumulative anthracycline dose of 
300 mg/m2). Baseline EKG, lipid profile, cardiac biomarkers troponin and pro-BNP, and seri-
al echocardiograms every 2–3 months were also recommended. Two decreases in ejection 
fraction (EF) to below normal limits (55% on August 2012 and 52% on April 2013), were 
managed by addition of lisinopril (2.5 mg daily) and metoprolol (12.5 mg daily), respective-
ly, which reversed the drop in EF (Fig. 3). 
In 2016, 6 years after diagnosis, nearly 5 years after initial AC treatment, and 2.5 years 
after termination of AC therapy, the patient remains minimally symptomatic on capecita-
bine, working full time with no cardiotoxicity and an excellent quality of life with her hus-
band and 6-year old daughter. 
Discussion 
Here, we describe a patient who achieved a complete response after cumulative doses of 
anthracyclines of 1,350 mg/m2, with well-managed normal cardiac function (as measured by 
echocardiogram) through the entire duration of treatment and for >2.5 years of follow-up. 
While we cannot rule out future late-onset cardiotoxicity (>2 years after treatment), most 
cardiotoxicity after anthracycline-containing therapy occurs within the first year [5]. Here, 
we will discuss what is currently known about anthracycline-induced cardiotoxicity, includ-
ing risk factors, molecular mechanisms, genetics, management, and limitations of current 
guidelines. 
The strongest predictor of anthracycline-induced cardiotoxicity is cumulative dose. In 
the most recent analysis of 630 patients from 3 prospective studies, the estimated cumula-
tive percentage of patients with doxorubicin-related cardiotoxicity (congestive heart failure) 
was 5% at a cumulative dose of 400 mg/m2, 26% at 550 mg, 48% at 700 mg/m2, and 100% 
above 800 mg/m2 [6]. In light of this analysis, the well-managed cardiotoxicity in our patient 
is remarkable. Additional well-characterized risk factors of anthracycline-induced cardiotox-
icity include coadministration of other cardiotoxic chemotherapeutic agents (e.g. 
trastuzumab), prior radiation to the mediastinum, older age, and pre-existing cardiovascular 
disease (e.g. hypertension, vascular disease, diabetes) [7, 8]. 
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Multiple hypotheses exist for the mechanism of anthracycline-mediated toxicity. The 
predominant hypothesis is treatment-induced increased production of toxic oxygen free 
radicals and oxidative stress, which leads to irreversible damage to myocytes and fibrosis of 
tissues [9]. Alternative hypotheses include myocyte damage due to (1) anthracycline inhibi-
tion of the beta isoform of topoisomerase-II (Top2), (2) calcium overload, (3) disruption of 
adrenergic function, (4) release of anthracycline metabolites, (5) release of vasoactive 
amines, and/or (6) release of proinflammatory cytokines [9, 10]. The lack of clear consensus 
despite a wealth of evidence suggests that the mechanism of anthracycline-induced cardio-
toxicity is likely multifactorial, and may differ on a case-by-case basis. 
Significant interindividual variability in the development of anthracycline-mediated 
cardiotoxicity has recently been attributed to genetics. Early data describes significant asso-
ciations between the incidence of cardiotoxicity and inherited polymorphisms in genes in-
volved in anthracycline metabolism (e.g. carbonyl reductase CBR1, CBR3), drug efflux (e.g. 
MRP1, MRP2), and reactive oxygen species generation (e.g. NAPD[H] oxidase), which have 
been further confirmed in functional animal studies [11, 12]. Genes involving cell survival 
(Hsp27, TLR2/4), DNA damage and repair (p53, Rac1), as well as transcriptional regulation 
(GATA4, STAT3, and AMPK) have also been implicated [13]. In this patient, molecular anal-
yses (DNA sequencing of custom 196-gene panel, chromosomal microarray) were per-
formed on tumor and plasma DNA, which revealed no known genetic alteration that could 
account for cardioprotection. However, we cannot rule out the possible contribution of an 
uncharacterized or undetected genetic mechanism. 
The management of anthracycline-mediated cardiotoxicity consists of constant monitor-
ing and treatment with cardioprotective agents. Several cardiac tests used successfully to 
detect or predict early changes in cardiac function or health include echocardiogram, radio-
nuclear cardiac imaging, cardiac MRI, electrocardiogram, and serum biomarkers such as 
troponin-T and NT pro-BNP [7]. Dexrazoxane has been clinically proven to significantly re-
duce the incidence of clinical and subclinical cardiotoxicity, and is currently recommended in 
metastatic patients who have received a cumulative dose of doxorubicin ≥300 mg/m2 [14]. 
Additional cardioprotective therapeutics used in preventative treatment include beta-
blocker (e.g. carvedilol) and ACE inhibitor (e.g. elanapril), which have also been used in 
combination to decrease the incidence of death, heart failure, or a final LVEF <45% in pa-
tients treated with anthracyclines [15]. Additional strategies to combat cardiotoxicity in-
clude the use of less toxic structural analogs of doxorubicin, such as epirubicin and mitoxan-
trone, or incorporation of anthracyclines into liposomes [7]. 
Several guidelines are available regarding the monitoring and management of anthracy-
cline-related cardiotoxicity [5]. These guidelines generally provide an upper limit for cumu-
lative dosages of anthracyclines based on cardiotoxicity data from retrospective analyses, 
generally recommending cumulative doses of less than 450–500 mg/m2 [7]. However, these 
guidelines are limited in that they fail to address high-risk patient populations where the 
benefit of higher cumulative doses of anthracyclines has the potential to outweigh the costs. 
This case thus highlights the need to establish evidence-based clinical guidelines for the 
monitoring and management of cardiotoxicity in these high-risk patient populations who 
respond to doxorubicin therapy. 
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Anthracyclines are an extremely effective chemotherapeutic agent, but concerns of car-
diotoxicity at higher doses prevents maximal therapeutic benefit of anthracycline treatment. 
Our case demonstrates that higher cumulative doses of anthracycline can be considered in 
high-risk patients with ongoing clinical benefit, and that maximum benefit-cost ratio from 
anthracyclines can be achieved through vigilant monitoring and managing of small changes 
in cardiac function. 
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Fig. 1. a Biopsy of the left breast reveals an extracellular mucin pool containing nests of neoplastic epitheli-
al cells, classic features of mucinous (colloid) carcinoma (HE. ×20). b–d The tumor cells in the CT-guided 
biopsy of the metastatic liver lesion shows similar morphology to the left breast lesion (b; HE. ×20). A total 
of 80–90% of tumor cells are strongly positive for ER (c; HE ×20) and ~5% are positive for PR with low 
intensity (d; HE ×20). HER2 fluorescence in situ hybridization (FISH) study performed on liver biopsy 
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Fig. 2. a Initial PET scan prior to treatment with doxorubicin shows multiple FDG-avid metastases 
throughout the liver (red arrow) and a large FDG-avid metastasis in the right acetabulum (blue arrow).  
b–d PET scans during therapy show decreasing metabolic tumor burden in the liver and in the right ace-
tabulum, achieving a complete metabolic response at both sites by the end of X cycles of doxorubicin. e The 
maximum standardized uptake value (SUV) of liver metastases decreases from the baseline pretreatment 
value of 5.6 to an end of treatment maximum SUV of 2.9 which is not significantly different than normal 




Fig. 3. Image showing EF (%) over time as measured by echocardiogram. Two points at the lower limit of 
normal or below the normal EF limit (arrows) were treated immediately with therapeutic intervention by 
cardiology, each of which was able to restore the EF to normal limits. The EF remained stable over the 
course of doxorubicin treatment and afterwards. Each point represents the date at which the patient had 
an echocardiogram. EF, ejection fraction. 
 
